Population pharmacokinetics of bictegravir in real-world people with HIV
Journal of Antimicrobial Chemotherapy · 03.10.2025 · 80 (10) · 2782-2789
DOI: 10.1093/jac/dkaf297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.08.2025. Verfasst von Pierre Ekobena und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: HIV Infections, Heterocyclic Compounds, 4 or More Rings, HIV Integrase Inhibitors, Pyridones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Bictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet. This study aimed to characterize bictegravir population PK in people with HIV (PWH) and to identify covariates affecting its disposition.
Methods
Bictegravir concentrations were obtained from PWH as part of a therapeutic drug monitoring (TDM) follow-up performed at the Lausanne University Hospital, Switzerland, between July 2019 and July 2024. Demographic data, clinical data and co-medications were recorded during the routine Swiss HIV Cohort Study (SHCS) visits. A population PK model was developed using a non-linear mixed-effect approach with Monolix®.
Results
A total of 708 steady-state plasma concentrations from 572 PWH were available for the analysis. A one-compartment model with first-order absorption and elimination best characterized bictegravir PK. Age and body weight were found to significantly affect bictegravir clearance, individuals of 51 years weighing 100 kg showing a 13% increase, and those aged 80 years weighing 70 kg a 11% decrease, relative to an individual weighing 70 kg and aged 51 years. These effects are not deemed clinically significant and do not warrant a clinical intervention.
Conclusions
Considering the good safety and efficacy profile of bictegravir, routine TDM is of limited value for bictegravir. However, TDM of bictegravir could be beneficial in case of suspected viral resistance or non-adherence, in special subpopulations (i.e. obese individuals and pregnant women), or to monitor drug–drug interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Otolaryngology and Head Neck Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
- Bio/CMOS Interfaces Laboratory, École Polytechnique Fédérale de Lausanne (EPFL), Neuchâtel, Switzerland.
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
- Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
ORCID-Profile: Kim Dao, Thierry Buclin, Matthias Cavassini, Monia Guidi, Paul Thoueille
Zitieren
APA
Ekobena, P., Briki, M., Dao, K., Marzolini, C., Andre, P., Buclin, T., Cavassini, M., Guidi, M., Thoueille, P., & Swiss HIV Cohort Study (2025). Population pharmacokinetics of bictegravir in real-world people with HIV. Journal of Antimicrobial Chemotherapy, 80(10), 2782-2789. https://doi.org/10.1093/jac/dkaf297
Vancouver
Ekobena P, Briki M, Dao K, Marzolini C, Andre P, Buclin T, et al. Population pharmacokinetics of bictegravir in real-world people with HIV. Journal of Antimicrobial Chemotherapy. 2025;80(10):2782-2789. doi:10.1093/jac/dkaf297
BibTeX
@article{Ekobena2025,
author = {Ekobena, Pierre and Briki, Myriam and Dao, Kim and Marzolini, Catia and Andre, Pascal and Buclin, Thierry and Cavassini, Matthias and Guidi, Monia and Thoueille, Paul and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
title = {Population pharmacokinetics of bictegravir in real-world people with HIV},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {10},
pages = {2782--2789},
doi = {10.1093/jac/dkaf297}
}
EUVIMED